5-Lipoxygenase-derived leukotrienes: Mediators also of atherosclerotic inflammation

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 7, 2003, Pages 1140-1142

  Rådmark, Olof ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; LEUKOTRIENE; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2;

AMINO ACID SEQUENCE; ATHEROGENESIS; ATHEROSCLEROSIS; EDITORIAL; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME STRUCTURE; ENZYME SYNTHESIS; HUMAN; INFLAMMATION; LIPID OXIDATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ANIMALS; ARACHIDONATE 15-LIPOXYGENASE; ARACHIDONATE 5-LIPOXYGENASE; ARTERIOSCLEROSIS; CELL MOVEMENT; HUMANS; LEUKOTRIENES; MACROPHAGES; MONOCYTES; PROTEIN CONFORMATION; VASCULITIS;

EID: 0038448178     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000082460.58448.01     Document Type: Editorial

References (34)

1. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med. 2002;8:1211-1217.
2. Brash AR. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem. 1999;274:23679-23682.
3. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001;294:1871-1875.
4. Radmark, O. Arachidonate 5-lipoxygenase. Prostaglandins Other Lipid Mediat. 2002;68-69:211-234.
5. Sparrow CP, Parthasarathy S, Steinberg D. Enzymatic modification of low density lipoprotein by purified lipoxygenase plus phospholipase A2 mimics cell-mediated oxidative modification. J Lipid Res. 1988;29: 745-753.
6. Kuhn H, Belkner J, Zaiss S, Fahrenklemper T, Wohlfeil S. Involvement of 15-lipoxygenase in early stages of atherogenesis. J Exp Med. 1994; 179:1903-1911.
7. Funk CD, Cyrus T. 12/15-lipoxygenase, oxidative modification of LDL and atherogenesis. Trends Cardiovasc Med. 2001;11:116-24.
8. Kuhn, H., Anton, M., Gerth, C, Habenicht, A. Amino acid differences in the deduced 5-lipoxygenase sequence of CAST Atherosclerosis-resistance mice confer impaired activity when introduced into the human ortholog. Arterioscler Thromb Vasc Biol. 2003;23:1072-1076.
9. Gillmor SA, Villasenor A, Fletterick R, Sigal E, Browner MF. The structure of mammalian 15-lipoxygenase reveals similarity to the lipases and the determinants of substrate specificity. Nat Struct Biol. 1997;4:1003-1009.
10. Peters-Golden M, Brock TG. Intracellular compartmentalization of leukotriene synthesis: unexpected nuclear secrets. FEBS Lett. 2001;487:323-326.
11. Spanbroek R, Grabner R, Lotzer K, Hildner M, Urbach A, Ruhling K, Moos MP, Kaiser B, Cohnert TU, Wahlers T, Zieske A, Plenz G, Robenek H, Salbach P, Kuhn H, Radmark O, Samuelsson B, Habenicht AJ. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA. 2003;100:1238-1243.
12. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995;92:1355-1374.
13. De Caterina R, Mazzone A, Giannessi D, Sicari R, Pelosi W, Lazzerini G, Azzara A, Forder R, Carey F, Caruso D, et al. Leukotriene B4 production in human atherosclerotic plaques. Biomed Biochim Acta. 1988;47: S182-S185.
14. Aiello RJ, Bourassa PA, Lindsey S, Weng W, Freeman A, Showell HJ. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol. 2002;22:443-449.
15. Bray MA, Ford-Hutchinson AW, Smith MJH. Leukotriene B4: biosynthesis and biological activities. In: Piper PJ, ed. SRS-A and Leukotrienes. New York, NY: John Wiley & Sons, Ltd; 1981:253-270.
16. Datta YH, Romano M, Jacobson BC, Golan DE, Serhan CN, Ewenstein BM. Peptido-leukotrienes are potent agonists of von Willebrand factor secretion and P-selectin surface expression in human umbilical vein endothelial cells. Circulation. 1995;92:3304-3311.
17. Eriksson EE, Xie X, Werr J, Thoren P, Lindbom L. Direct viewing of atherosclerosis in vivo: plaque invasion by leukocytes is initiated by the endothelial selectins. FASEB J. 2001;15:1149-1157.
18. Mehrabian M, Wong J, Wang X, Jiang Z, Shi W, Fogelman AM, Lusis AJ. Genetic locus in mice that blocks development of atherosclerosis despite extreme hyperlipidemia. Circ Res. 2001;89:125-130.
19. Mehrabian M, Allayee H, Wong J, Shi W, Wang XP, Shaposhnik Z, Funk CD, Lusis AJ. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res. 2002;91:120-126.
20. Chen XS, Sheller JR, Johnson EN, Funk CD. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature. 1994; 372:179-182.
21. Goulet JL, Snouwaert JN, Latour AM, Coffman TM, Koller BH. Altered inflammatory responses in leukotriene-deficient mice. Proc Natl Acad Sci USA. 1994;91:12852-12856.
22. Shimizu T, Radmark O, Samuelsson B. Enzyme with dual lipoxygenase activities catalyzes leukotriene A4 synthesis from arachidonic acid. Proc Natl Acad Sci USA. 1984;81:689-693.
23. Jones SM, Luo M, Healy AM, Peters-Golden M, Brock TG. Structural and functional criteria reveal a new nuclear import sequence on the 5-lipoxygenase protein. J Biol Chem. 2002;277:38550-38556.
24. Hammarberg T, Provost P, Persson B, Radmark O. The N-terminal domain of 5-lipoxygenase binds calcium and mediates calcium stimulation of enzyme activity. J Biol Chem. 2000;275:38787-38793.
25. Chen XS, Funk CD. The N-terminal "beta-barrel" domain of 5-lipoxygenase is essential for nuclear membrane translocation. J Biol Chem. 2001;276:811-818.
26. Kulkarni S, Das S, Funk CD, Murray D, Cho W. Molecular basis of the specific subcellular localization of the C2-like domain of 5-lipoxygenase. J Biol Chem. 2002;277:13167-13174.
27. Werz O, Klemm J, Samuelsson B, Radmark O. 5-Lipoxygenase is phosphorylated by p38 kinase dependent MAPKAP kinases. Proc Natl Acad Sci U S A. 2000;97:5261-5266.
28. Werz O, Szellas D, Steinhilber D, Radmark O. Arachidonic acid promotes phosphorylation of 5-lipoxygenase at Ser-271 by MAPK-activated protein kinase 2 (MK2). J Biol Chem. 2002;277:14793-14800.
29. Werz O, Bürkert E, Samuelsson B, Radmark O, Steinhilber D. Activation of 5-lipoxygenase by cell stress is calcium independent in human polymorphonuclear leukocytes. Blood. 2002;99:1044-1052.
30. Werz O, Klemm J, Radmark O, Samuelsson B. p38 MAP kinase mediates stress-induced leukotriene synthesis in a human B-lymphocyte cell line. J Leuk Biol. 2001;70:830-838.
31. Hatzelmann A, Ullrich V. Regulation of 5-lipoxygenase activity by the glutathione status in human polymorphonuclear leukocytes. Eur J Biochem. 1987;169:175-184.
32. Folcik VA, Cathcart MK. Assessment of 5-lipoxygenase involvement in human monocyte-mediated LDL oxidation. J Lipid Res. 1993;34:69-79.
33. Serhan CN. Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution. Prostaglandins Other Lipid Mediat. 2002;68-69: 433-455.
34. Powell WS, Boismenu D, Khanapure SP, Rokach J. Quantitative analysis of 5-oxo-6, 8, 11, 14-eicosatetraenoic acid by electrospray mass spectrometry using a deuterium-labeled internal standard. Anal Biochem. 2001;295:262-266.